

Figure 2: Jenner-Giemsa stain and quantification of C2C12 differentiated myotubes displays a decrease in myotube fusion among the FX1-treated group



Figure 1: Crystal Violet Assay stain and quantification displaying decreased number of myoblasts in FX1- treated group. ECHO Revolve Microscope was used to evaluate the extent of proliferation of C2C12 myoblasts. The Crystal Violet Assay was conducted on C2C12 myoblasts showing the DMSO-treated group (left) and the FX1-treated group (right). Each 6-well plate sample had a seeding density of 300,000 and has been proliferating for 24 hours in either DMSO or FX1. The FX1-treated group displays a profound decrease of cells, based on the amount of stain in the visual field. $n = 3$, $p < 0.0001$ (****) determined by 2-tailed student t-test. The second analysis (B) had FX1 added after the first day of seeding and was stained after Days 1, 2, and 3. $n=3$, $p < 0.1$ (*), $p < 0.01$ (**), $p < 0.0001$ (****) determine by 2-tailed student t-test. All calculations for statistical significance in this project were done with two-tailed student t-tests between each group as determined by GraphPad Prism (Version 7).